Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024

Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr

Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24

Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility

The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities

Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion

Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion

Gland Pharma posts Q2 FY25 consolidated profit at Rs. 163.53 Cr

The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024

Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies

Emcure Pharma forms subsidiary to strengthen dermatology portfolio

The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore

Yatharth Hospitals acquires 60% stake in 400-bedded hospital in Faridabad for Rs. 91 Cr

USFDA inspection of Shilpa Medicare Unit VI at Bengaluru

The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature